Brief: Quince Marks Final Patient Visit in NEAT Phase 3 Study
15/12/2025 14:53
Dec 15 (Reuters) - Quince Therapeutics Inc QNCX.O: QUINCE THERAPEUTICS ANNOUNCES LAST PATIENT LAST VISIT IN PHASE 3 NEAT CLINICAL TRIAL IN PATIENTS WITH ATAXIA-TELANGIECTASIA QUINCE THERAPEUTICS - EXPECTS TOPLINE RESULTS IN Q1 2026 Source text: ID:nBw3kRP1Da Further company coverage: QNCX.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on IRulya Therapeutics
See all newsBrief: Quince Therapeutics - Changes Name To Irulya Therapeutics
Brief: Quince Therapeutics - Appoints Brigette Roberts As CEO Effective October 8, 2026
Quince Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Brief: Quince Therapeutics Reports Second Quarter 2026 Financial Results And Corporate Update
Quince Therapeutics Q2 net loss widens on acquisition charges